Vivek Subbiah: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, posted on X about recent paper by Jia Liu et al., titled “Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials” published on Journal of Clinical Oncology.
Authors: Jia Liu, Max Farrow, Lesley Seymour, Jayesh Desai, Herbert H. Loong, Percy Ivy, Takafumi Koyoma, Natalie Cook, Sarah Blagden, Elena Garralda, Christophe Massard, Anthony W. Tolcher, Jacob J. Adashek, Li Zhang, Shen Zhao, Lin Shen, Razelle Kurzrock, Wafik S. El-Deiry, Vivek Subbiah, Anthony M. Joshua.
“Nice overview in JCO Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials. Terrific work by
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023